Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo
Open Access
- 24 March 2017
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 216
Abstract
Former studies already revealed the anti-neoplastic properties of the anti-infective agent Taurolidine (TRD) against many tumor species in vitro and in vivo. Its anti-proliferative and cell death inducing capacity is largely due to its main derivative Taurultam (TRLT). In this study it could be demonstrated, that substance 2250 - a newly defined innovative structural analogue of TRLT - exhibits an anti-neoplastic effect on malignant pancreatic carcinoma in vitro and in vivo. The anti-neoplastic potential of substance 2250 as well as its mode of action was demonstrated in extensive in vitro analysis, followed by successful and effective in vivo testings, using xenograft models derived from established pancreatic cancer cell lines as well as patient derived tissue. Our functional analysis regarding the role of oxidative stress (ROS) and caspase activated apoptosis showed, that ROS driven programmed cell death (PCD) is the major mechanisms induced by substance 2250 in pancreatic carcinoma. What is strongly relevant towards clinical practice is especially the observed inhibition of patient derived pancreatic cancer tumor growth in mice treated with this new substance in combination with its sharply higher metabolic stability. These encouraging results provide new therapeutical opportunities in pancreatic cancer treatment and build the basis for further functional analysis as well as first clinical studies for this promising agent.Keywords
This publication has 47 references indexed in Scilit:
- A Cell-Permeant Amiloride Derivative Induces Caspase-Independent, AIF-Mediated Programmed Necrotic Death of Breast Cancer CellsPLOS ONE, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell linesJournal of Experimental & Clinical Cancer Research, 2010
- Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: a multicentre prospective randomized trialWorld Journal of Surgical Oncology, 2009
- Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl‐2 family proteinsJournal of Surgical Oncology, 2007
- Pharmacokinetics of Taurolidine following Repeated Intravenous Infusions Measured by HPLC-ESI-MS/MS of the Derivatives Taurultame and Taurinamide in Glioblastoma PatientsClinical Pharmacokinetics, 2007
- Impact of taurolidine on the growth of CC531 coloncarcinoma cells in vitro and in a laparoscopic animal model in ratsSurgical Endoscopy, 2004
- The influence of adhesion prophylactic substances and taurolidine/heparin on local recurrence and intraperitoneal tumor growth after laparoscopic-assisted bowel resection of colon carcinoma in a rat modelSurgical Endoscopy, 2003
- Reduced adherence of micro‐organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agentJournal of Applied Bacteriology, 1987
- Acetosulfam, ein neuer S stoffEuropean Food Research and Technology, 1976